Brief: Silo Pharma Achieves Key Milestone With First Dosing In IND-Enabling GLP Study For SPC-15 As A Groundbreaking PTSD Treatment
26/03/2025 12:44
March 26 (Reuters) - Silo Pharma Inc SILO.O: SILO PHARMA ACHIEVES KEY MILESTONE WITH FIRST DOSING IN IND-ENABLING GLP STUDY FOR SPC-15 AS A GROUNDBREAKING PTSD TREATMENT Source text: ID:nGNX1dmswz Further company coverage: SILO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement